It's important to remember the ongoing controversial statements by the creator of the Harry Potter franchise. CBR supports ...

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Sadly, some of the strongest characters that stand out in the books didn't make it into any of the Harry Potter movies.